Deerfield Management Company, L.P. (Series C) Bluebird Bio, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$3.14 - $8.22 $6.83 Million - $17.9 Million	2,175,000 New	2,175,000 $6.92 Million
Q3 2021 Nov 15, 2021	SELL	$11.24 - $21.0 $5.4 Million - $10.1 Million	-480,300 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$16.59 - $33.89 $7.97 Million - $16.3 Million	480,300 New	480,300 $14.5 Million
Q4 2018 Feb 14, 2019	SELL	$59.1 - $93.26 $3.63 Million - $5.73 Million	-61,435 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$88.86 - $117.49 $4.58 Million - $6.06 Million	-51,565 Reduced 45.63%	61,435 $8.97 Million
Q2 2018 Aug 14, 2018	BUY	$99.64 - $127.59 $7.17 Million - $9.19 Million	72,000 Added 175.61%	113,000 $17.7 Million
Q1 2018 May 15, 2018	SELL	$105.8 - $150.94 $4.13 Million - $5.89 Million	-39,000 Reduced 48.75%	41,000 $7 Million
Q4 2017 Feb 14, 2018	BUY	$81.25 - $130.7 $6.5 Million - $10.5 Million	80,000	80,000 $14.2 Million

Others Institutions Holding BLUE

# of Institutions

151

Shares Held

63.4M

Call Options Held

264K

Put Options Held

428K

Black Rock Inc. New York, NY

15.4M
Shares

$5.71 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

10.5M
Shares

$3.88 Million
0.0% of portfolio
Geode Capital Management, LLC Boston, MA

4.68M
Shares

$1.73 Million
0.0% of portfolio
Pictet Asset Management Sa Geneva 73, V8

4.67M
Shares

$1.73 Million
0.02% of portfolio
State Street Corp Boston, MA

3.84M
Shares

$1.42 Million
0.0% of portfolio

View Full List

About bluebird bio, Inc.

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $28.5M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

More about BLUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account